Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non‐small‐cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage

Abstract

Simultaneous panel genotyping revealed more prevalent ALK rearrangements than reported in previous studies and their strong association with advanced stage irrespective of sex or smoking history. ALK rearrangement seems to be a marker for aggressive tumor biology and should be assessed in advanced disease.

References

Page 1

	Year	Citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, New England Journal of Medicine	2004	11.4K
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, New England Journal of Medicine	2010	4.5K
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers Hisayuki Shigematsu, Tsuyoshi Takahashi, Masatoshi Nomura, JNCI Journal of the National Cancer Institute	2005	2.4K
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer Klarisa Rikova, Ailan Guo, Qingfu Zeng, Cell OncologyMedicineGlobal SurveyReceptor Tyrosine KinaseBronchial Neoplasm	2007	2.3K
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i> Alice T. Shaw, Beow Y. Yeap, Mari Mino–Kenudson, Journal of Clinical Oncology	2009	1.9K
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley, Journal of Thoracic Oncology	2013	1.3K
<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer Jussi Koivunen, Craig H. Mermel, Kreshnik Zejnullahu, Clinical Cancer Research	2008	974
The <i>EML4‐ALK</i> fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type <i>EGFR</i> and <i>KRAS</i> Daisy Wing‐Sze Wong, Elaine Lai‐Han Leung, Kimpton Kam‐Ting So, Cancer	2009	704
Unique Clinicopathologic Features Characterize <i>ALK</i> -Rearranged Lung Adenocarcinoma in the Western Population Scott J. Rodig, Mari Mino–Kenudson, Beow Y. Yeap, Clinical Cancer Research	2009	679
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials Daphne W. Bell, Thomas J. Lynch, Sara M. Haserlat, Journal of Clinical Oncology	2005	607

Page 1